“clinical-trials” Archives

in
Entry Author Date Location
Corbus Shares Climb on Early Data For Inflammation Drug 11/14/16 Boston
New Data Show Biogen, Ionis Drug Might Help More With Rare Spine Disease 11/07/16 Boston
Bio Roundup: Clinical Shirkers, AMD Worriers, ASH Fallers & More 11/04/16 National
Flatiron, Foundation Med Link Records of 20,000 Cancer Patients 11/03/16 New York
New Data Show Power, Limits of Bluebird’s Gene Therapy For Blood Diseases 11/03/16 Boston
Verastem Takes a Low-Cost Flier on Infinity’s Blood Cancer Drug 11/02/16 Boston
On Front Lines Of Price Dispute, Eye Doctors Wary of New Drug Data 11/01/16 National
FDA: Keytruda Now OK For Some Patients With Untreated Lung Cancer 10/25/16 National
Safety Issue Triggers Partial FDA Hold for Aduro Bio 10/24/16 San Francisco
Alkermes Eyes FDA Nod After Retooled Study Yields Desired Results 10/20/16 Boston
Roundup: J&J and AT&T Grow in Houston, Inspyr and Meshify Move On 10/19/16 Texas
All In One Place: A New Immuno-Oncology Trial Resource 10/19/16 National
Early Data for Celgene’s Oral Crohn’s Drug Gets Mixed Reaction 10/17/16 New York
Weeks After Deal, FDA Slaps Clinical Hold on Regeneron/Teva Pain Drug 10/17/16 New York
Bio Roundup: Bristol & Illumina Blues, Sickle Cell News & More 10/14/16 National
With Upgraded Tech, Bluebird Updates Regulatory Path For Gene Therapy 10/13/16 Boston
Bay Area Researchers Take A CRISPR Cut At Sickle Cell Disease 10/12/16 San Francisco
Checkpoints In Lung Cancer, and Other Oncology News From Europe 10/11/16 National
Defying Patient Pressure, Anthem Says No to Sarepta’s Duchenne Drug 10/07/16 Boston
Alnylam Scraps RNAi Drug After Safety Problems, Shares Plunge 10/05/16 Boston
Post FDA Approval, Sarepta Wheels and Deals for Combo Duchenne Drugs 10/04/16 Boston
Taking Aim at Alexion, Ra Pharma Heads to IPO Queue 10/03/16 Boston
Will Programmable Immune “Cellbots” Be the Next Weapon Against Cancer? 09/29/16 San Francisco
Genocea Touts Early Look at Placebo-Controlled Herpes Vaccine Study 09/29/16 Boston
Intra-Cellular Shares Sink As Schizophrenia Drug Flunks Final Test 09/28/16 New York
Bio Execs Talk Patient Advocacy, Duchenne Approval at BioForward Panel 09/28/16 Wisconsin
Kite Unveils Anticipated CAR-T Cancer Data: Positive But Not Complete 09/26/16 National
Sarepta Preps For Sales As Insurers Unlikely To Deny Duchenne Drug 09/22/16 Boston
Eleven Bio Buys Viventia, Rebrands as Cancer Drug Developer 09/21/16 Boston
With Tobira Deal, Allergan Keeps Shopping For “Questionable” Assets 09/20/16 San Francisco
Page 2 of 21 « previous page · next page »